Article
Medicine, Research & Experimental
Hualong Bai, Liwei Zhang, Peng Sun, Haoliang Wu, Mingxing Li, Yulei Gu, Cong Zhang, Chunyang Lou, Jing'an Li
Summary: This study investigates the role of ADAM17 in the formation and progression of abdominal aortic aneurysms (AAAs). The results show that inhibiting ADAM17 can decrease AAA formation and progression in mouse and rat models. ADAM17 was found to be highly expressed in mouse, rat, and human aneurysms. The study suggests that ADAM17 could be a potential treatment target for AAAs.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Cell Biology
Xinping Zhu, Masahisa Kudo, Xiangjie Huang, Hehuan Sui, Haishan Tian, Carlo M. Croce, Ri Cui
Summary: Lung cancer, particularly NSCLC, is a major cause of cancer-related deaths globally. Recent advancements in treatment have improved therapeutic efficacy, but the survival rate remains low due to inadequate screening methods and late onset of symptoms. Dysregulation of miRNAs in NSCLC plays a critical role in development, progression, and metastasis, presenting potential for diagnostic and therapeutic applications.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jinsong Lei, Guangran Guo, Dachuan Liang, Li Gong, Linjie Zhang, Xin Wang
Summary: The study revealed the correlation between ARGs and tumor prognosis in NSCLC, and constructed a prognostic signature based on ARGs. Functional analysis indicated enrichment in apoptotic signaling pathway, collagen-containing ECM, and integrin binding, and an association with the PI3K-Akt signaling pathway. Furthermore, the high-risk group in NSCLC had a worse prognosis, with higher M0 and M2 macrophage infiltration, fewer CD8 T-cells and T follicular helper (TFH) cells, and less benefit from ICI therapy.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Chemistry, Multidisciplinary
Jian Zhang, Bin Fu, Meng Li, Shuangli Mi
Summary: This study uses quantitative proteomics to identify diagnostic markers and a prognostic signature based on differential protein secretion by normal fibroblasts and exosome-activated fibroblasts affected by lung cancer cell-derived exosomes. These findings have the potential to distinguish tumor tissues from normal tissue and identify patients who may benefit from adjuvant therapy after surgical resection. Additionally, the secretome offers novel targets for clinical treatment.
Article
Oncology
Ling Li, Bao-jia Zou, Juan-zhi Zhao, Jia-bi Liang, Zi-yue She, Wen-ying Zhou, Si-xiao Lin, Lin Tian, Wen-ji Luo, Fa-zhong He
Summary: This study systematically analyzes the relationship between DDR alterations and NSCLC prognosis, establishes a six-DDR gene prognostic model, and finds that high-risk patients are more responsive to immunotherapy while low-risk patients are more sensitive to DNA-damaging chemotherapy drugs.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Alissa J. Cooper, Lecia Sequist, Ted W. Johnson, Jessica J. Lin
Summary: The discovery of CLIP1-LTK fusion as an oncogenic driver in lung cancer and its targetability with ALK tyrosine kinase inhibitor lorlatinib has significant implications for the diagnosis and treatment of non-small cell lung cancer.
Article
Cell Biology
Danielle S. Potter, Ruochen Du, Patrick Bhola, Raphael Bueno, Anthony Letai
Summary: By utilizing dynamic BH3 profiling (DBP) to measure drug-induced mitochondrial apoptotic priming, it is possible to identify drugs that render tumors more sensitive to conventional chemotherapy and to rationally construct combination therapies. Research has shown that targeted agents that increase priming of NSCLC tumor cells can enhance sensitivity to chemotherapy both in vitro and in vivo.
CELL DEATH & DISEASE
(2021)
Article
Genetics & Heredity
Qiushi Xu, Tong Liu, Junjie Wang
Summary: A new treatment modality targeting cuproptosis is emerging, with a predictive lncRNA signature associated with cuproptosis developed to predict the prognosis of NSCLC patients following radiation, providing a novel clinical strategy.
Article
Nanoscience & Nanotechnology
Yao Chen, Shuya Liu, Yin Liao, Hanshan Yang, Zhuo Chen, Yuru Hu, Shaozhi Fu, Jingbo Wu
Summary: In this study, albumin-modified gold nanoparticles (Alb-GNPs) were prepared and their radiosensitizing effects and biotoxicity in human non-small-cell lung carcinoma tumor-bearing mice models were observed. The prepared nanoparticles (Alb-GNPs) showed excellent colloidal stability and biocompatibility with a mean size of 205.06 +/- 1.03 nm. Clone formation experiments demonstrated that Alb-GNPs exerted excellent radiosensitization with a higher sensitization enhancement ratio (SER) of 1.432 compared to X-ray alone. Alb-GNPs could accumulate favorably in tumors and their combination with radiotherapy exhibited a greater radiosensitizing effect and anti-tumor activity. Additionally, no toxicity or abnormal irritating response was observed with the application of Alb-GNPs.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Pharmacology & Pharmacy
Meng Chi, Yamin Jie, Ying Li, Duo Wang, Man Li, Dan Li, Mingyan E, Yongwu Li, Na Liu, Anxin Gu, Guanghua Rong
Summary: A novel small-molecule inhibitor, Compound 2b, targeting ADAM17/Notch pathway, was designed and developed for the treatment of NSCLC. It effectively inhibited the cleavage of Notch proteins and the accumulation of Notch intracellular domain, enhancing the therapeutic efficacy of antitumor drugs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Andrew M. Baschnagel, Jacob H. Elnaggar, Haley J. VanBeek, Ashley C. Kromke, Justin H. Skiba, Saakshi Kaushik, Lindsey Abel, Paul A. Clark, Colin A. Longhurst, Kwangok P. Nickel, Ticiana A. Leal, Shuang G. Zhao, Randall J. Kimple
Summary: The study found enrichment of DDR pathways in many NSCLC patient tumors. M6620 can enhance the effect of radiation on NSCLC brain metastases, leading to improved overall survival in mice when used in combination with radiation.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Chang Jiang, Nathan P. Ward, Nicolas Prieto-Farigua, Yun Pyo Kang, Anish Thalakola, Mingxiang Teng, Gina M. DeNicola
Summary: The redox regulator NRF2 is hyperactivated in a large percentage of non-small cell lung cancer (NSCLC) cases, which is associated with chemotherapy and radiation resistance. In this study, the researchers identified that the loss of mitochondrial superoxide dismutase 2 (SOD2) enhanced the effectiveness of a superoxide-generating drug, beta-Lapachone. They also found that inhibiting mitochondrial electron transport activity sensitized cells to beta-Lapachone. These findings suggest potential therapeutic strategies to increase ROS sensitivity in NSCLC.
Article
Immunology
Chengming Liu, Sihui Wang, Sufei Zheng, Fei Xu, Zheng Cao, Xiaoli Feng, Yan Wang, Qi Xue, Nan Sun, Jie He
Summary: Immunotherapy has drawn significant attention in oncology, but traditional biomarkers for anti-PD-1 therapy may not be suitable for NSCLC clinical practice due to technical biases. The novel BRGPI, a gene expression-based index, showed strong potential as a predictive tool for identifying NSCLC patients who may benefit from anti-PD-1 immunotherapy, outperforming PD-L1 as a prognostic factor. Patients with low BRGPI and high PD-L1 levels were found to derive more clinical benefits from anti-PD-1 therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Shunsuke Misono, Keiko Mizuno, Takayuki Suetsugu, Kengo Tanigawa, Nijiro Nohata, Akifumi Uchida, Hiroki Sanada, Reona Okada, Shogo Moriya, Hiromasa Inoue, Naohiko Seki
Summary: Small cell lung cancer (SCLC) is a fatal tumor with poor prognosis in patients who relapse after initial treatment. This study identified a molecular signature of SCLC after treatment failure, focusing on genes related to the cell cycle pathway. The overexpression of MCM2, MCM4, MCM6, and MCM7 was detected in SCLC clinical specimens, suggesting their potential as therapeutic targets. Knockdown of these MCM genes attenuated cancer cell proliferation and enhanced cisplatin sensitivity in SCLC cells, indicating their role in treatment resistance.
Review
Biochemistry & Molecular Biology
Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, Massimiliano Grassi, Veronica Murianni, Marco Tagliamento, Arsela Prelaj, Simona Coco, Luca Longo, Maria Giovanna Dal Bello, Angela Alama, Chiara Dellepiane, Elisa Bennicelli, Umberto Malapelle, Carlo Genova
Summary: In the systemic treatment of advanced NSCLC patients, targeted therapies such as EGFR, ALK, ROS1, and BRAF inhibitors have been significant breakthroughs. In addition to these known molecular drivers, potential therapeutic targets including MET, RET, NTRK, KRAS, PIK3CA, and HER2 are rapidly emerging. Research on these emerging molecular targets is crucial to increasing the proportion of patients benefiting from tailored therapeutic approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ivo Grgic, Fabienne Tschanz, Nathalie Borgeaud, Anurag Gupta, Pierre-Alain Clavien, Matthias Guckenberger, Rolf Graf, Martin Pruschy
Summary: ITPP induces tumor oxygenation and enhances DNA damage, promoting radiosensitization and reducing tumor growth when combined with ionizing radiation. The combined treatment modality also protects tumor vasculature, prevents tumor hypoxia, and increases immune cell infiltration, ultimately enhancing the efficacy of radiation therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Tamara Kazimova, Fabienne Tschanz, Ashish Sharma, Irma Telarovic, Marco Wachtel, Gloria Pedot, Beat Schaefer, Martin Pruschy
Summary: Placental growth factor (PlGF) is regulated by p53 in response to ionizing radiation and plays a protective role in tumor angiogenesis. Studies suggest that targeting PlGF may be a promising approach for combined treatment with radiotherapy to improve therapeutic outcomes.
MOLECULAR CANCER RESEARCH
(2021)
Review
Oncology
Adela Ademaj, Danai P. Veltsista, Pirus Ghadjar, Dietmar Marder, Eva Oberacker, Oliver J. Ott, Peter Wust, Emsad Puric, Roger A. Haelg, Susanne Rogers, Stephan Bodis, Rainer Fietkau, Hans Crezee, Oliver Riesterer
Summary: This review examines the existing clinical evidence regarding the correlation between thermometric parameters and cancer response in patients treated with hyperthermia (HT) in combination with radiotherapy (RT) and/or chemotherapy (CT). Some studies indicate that thermometric parameters correlate with treatment response, suggesting their potential significance for treatment guidance.
Article
Oncology
Simon Deycmar, Elisabeth Mara, Sylvia Kerschbaum-Gruber, Verena Waller, Dietmar Georg, Martin Pruschy
Summary: The radiosensitizing effect of HSP90 inhibitor ganetespib was investigated for proton irradiation and photon irradiation. It was found that low-dose ganetespib significantly increased the killing effect of proton irradiation on cancer cells, while having minimal effect on photon irradiation. This provides a theoretical basis for future combinatorial approaches with proton radiotherapy.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Emanuel Stutz, Emsad Puric, Adela Ademaj, Arnaud Kuenzi, Reinhardt Krcek, Olaf Timm, Dietmar Marder, Markus Notter, Susanne Rogers, Stephan Bodis, Oliver Riesterer
Summary: Reimbursement status and patterns of care for deep hyperthermia in Switzerland are analyzed, providing insights for national standardization and quality assurance of deep hyperthermia treatment schedules.
Article
Gastroenterology & Hepatology
Henry L. Y. Chan, Arndt Vogel, Thomas Berg, Enrico N. De Toni, Masatoshi Kudo, Joerg Trojan, Anja Eiblmaier, Hanns-Georg Klein, Johannes Kolja Hegel, Ashish Sharma, Kairat Madin, Vinzent Rolny, Marcus-Rene Lisy, Teerha Piratvisuth
Summary: The Elecsys PIVKA-II assay was evaluated for its clinical and analytical performance in diagnosing hepatocellular carcinoma (HCC). It showed good performance and comparable clinical results to other comparator assays. The Elecsys PIVKA-II assay can be considered as a useful tool for HCC diagnosis.
Article
Oncology
Oliver Riesterer, Adela Ademaj, Emsad Puric, Brigitte Eberle, Marcus Beck, Silvia Gomez, Dietmar Marder, Eva Oberacker, Susanne Rogers, Roger A. Haelg, Thomas Kern, Sonja Schwenne, Jurgen Stein, Emanuel Stutz, Olaf Timm, Sebastian Zschaeck, Mathias S. Weyland, Paraskevi D. Veltsista, Stephen Wyler, Peter Wust, Stephan Scheidegger, Stephan Bodis, Pirus Ghadjar
Summary: This study investigated the efficacy of a tetramodal approach with additional regional hyperthermia in patients with muscle-invasive bladder cancer (MIBC), and the results showed that this treatment method has excellent local response, moderate toxicity, and good quality of life.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2022)
Letter
Oncology
Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli, Martin Behe
Summary: Our study compares the cellular responses to external beam radiation therapy (EBRT) and internal targeted radionuclide therapy (TRT). We found that TRT robustly activates signaling pathways in cancer cells, including EGFR, MAPKs, and integrin receptor. Inhibiting these pathways increases the sensitivity of cancer cells to radiolabeled minigastrin. In vivo experiments showed that EGFR inhibitor erlotinib enhances therapeutic response and prolongs the survival of nude mice.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Irma Telarovic, Carmen S. M. Yong, Matthias Guckenberger, Jan Unkelbach, Martin Pruschy
Summary: Radiation-induced lymphopenia is associated with radiotherapy treatment volume, and the combination of radiotherapy and immunotherapy plays a crucial role in treatment efficacy.
Article
Oncology
Adela Ademaj, Emsad Puric, Olaf Timm, David Kurti, Dietmar Marder, Thomas Kern, Roger A. Haelg, Susanne Rogers, Oliver Riesterer
Summary: Hyperthermia (HT) combined with radio(chemo)therapy (RCT) is an established cancer treatment strategy. This study assessed the quality of life (QoL), toxicity, and survival outcomes in patients who received HT in combination with RCT for different tumor types. The results showed that combinatorial therapy improved QoL and had acceptable toxicity, with favorable overall survival and local progression-free survival rates.
Article
Oncology
Stefan Bornstein, Igor Shapiro, Alekhya Mazumdar, Kathrin Zitzmann, Svenja Noelting, Edlira Luca, Felix Beuschlein, Ashish Sharma, Constanze Hantel
Summary: This study reveals a previously unexplored role of the vault complex in endocrine tumor therapeutic responsiveness, involving the synthesis and release of vault RNA and the regulation of intracellular autophagy and the CLEAR network.
Article
Oncology
Adela Ademaj, Emsad Puric, Dietmar Marder, Olaf Timm, Thomas Kern, Roger A. Halg, Susanne Rogers, Oliver Riesterer
Summary: Radiotherapy combined with deep regional hyperthermia is a promising organ-preservation therapy for elderly and frail patients with muscle-invasive bladder cancer, as it can effectively control local progression of the tumor while avoiding systemic toxicities.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2023)
Review
Chemistry, Multidisciplinary
Lukas R. H. Gerken, Maren E. Gerdes, Martin Pruschy, Inge K. Herrmann
Summary: Radiotherapy is an important component of solid cancer treatment, but its efficacy is limited by the co-irradiation of organs at risk and subsequent normal tissue toxicities. Nanotechnology offers an attractive solution by designing engineered nanomaterials as radiosensitizers or radioenhancers. Recent research challenges the concept of high-Z nanoparticle radioenhancers and emphasizes the importance of catalytic activity. This review provides a concise overview of nanoparticle radioenhancement mechanisms, discusses potential candidate materials, and highlights research priorities for advancing nanomaterial development and improving the efficacy of radiotherapy.
MATERIALS HORIZONS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Henry L. Y. Chan, Arndt Vogel, Thomas Berg, Enrico de Toni, Masatoshi Kudo, Jorg Trojan, Katharina Malinowsky, Peter Findeisen, Hanns-Georg Klein, Johannes Kolja Hegel, Wenzel Schoening, Konstantin Kroeniger, Kairat Madin, Ashish Sharma, Teerha Piratvisuth
JOURNAL OF HEPATOLOGY
(2022)